The State Street SPDR S&P Biotech ETF (XBI) experienced a significant outflow of approximately $945.9 million, marking a 10.5% decrease in shares outstanding from 69,850,000 to 62,525,000 over the past week. This change reflects changing investor sentiment in biotech holdings amidst market fluctuations.
Currently, XBI’s share price stands at $129.18, which is well-positioned between its 52-week low of $66.66 and a high of $132.09. Key components of the ETF include Moderna Inc (MRNA), up 4.3%, Roivant Sciences Ltd (ROIV), gaining 1.4%, and Revolution Medicines Inc (RVMD), which increased by 0.6%.
